{"id":"sustained-release-morphine-sulfate","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Constipation"},{"rate":"20-30","effect":"Nausea"},{"rate":"20-30","effect":"Drowsiness"},{"rate":"10-20","effect":"Dizziness"},{"rate":"10-15","effect":"Vomiting"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Dependence/tolerance"}]},"_chembl":{"chemblId":"CHEMBL2103744","moleculeType":"Small molecule","molecularWeight":"758.84"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Morphine is a mu-opioid receptor agonist that modulates pain perception and emotional response to pain by acting on opioid receptors throughout the brain and spinal cord. The sustained-release formulation provides extended drug delivery over 12-24 hours, maintaining therapeutic levels and reducing dosing frequency compared to immediate-release formulations. This allows for more consistent analgesia in chronic pain management.","oneSentence":"Sustained-release morphine sulfate binds to opioid receptors in the central nervous system to provide prolonged pain relief.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:20.750Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain requiring continuous opioid therapy"},{"name":"Cancer pain"}]},"trialDetails":[{"nctId":"NCT05265052","phase":"PHASE2","title":"3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain","status":"NOT_YET_RECRUITING","sponsor":"3D Medicines","startDate":"2026-12","conditions":"Cancer Pain","enrollment":177},{"nctId":"NCT04785768","phase":"PHASE3","title":"IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2021-07-01","conditions":"Cancer Pain","enrollment":1372},{"nctId":"NCT06897917","phase":"PHASE4","title":"Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-04","conditions":"Opioid-Induced Constipation, Pain Cancer","enrollment":203},{"nctId":"NCT05375916","phase":"NA","title":"Comparison of Short-term Sustained-release Opioid in Open Abdominal Urologic Surgeries","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2022-05-03","conditions":"Pain, Acute, Opioid Use","enrollment":80},{"nctId":"NCT04243954","phase":"PHASE2","title":"Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2020-04-10","conditions":"Cancer Pain","enrollment":95},{"nctId":"NCT00726830","phase":"NA","title":"Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03","conditions":"Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia","enrollment":1},{"nctId":"NCT04549818","phase":"NA","title":"Analgesic Efficacy of Sacral Neuromodulation for Pelvic Cancer Pain: A Preliminary Report","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-09-10","conditions":"Chronic Pain","enrollment":44},{"nctId":"NCT00782548","phase":"PHASE4","title":"Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2004-05","conditions":"Healthy","enrollment":40},{"nctId":"NCT04132011","phase":"PHASE4","title":"Dosing Intervals of Opioid Medication for Chronic Pain","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2019-05-01","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT02720822","phase":"PHASE3","title":"Breathlessness Exertion and Morphine Sulphate","status":"COMPLETED","sponsor":"Flinders University","startDate":"2016-08-08","conditions":"Chronic Obstructive Pulmonary Disease, Dyspnea","enrollment":171},{"nctId":"NCT02429050","phase":"PHASE4","title":"Morphine for Treatment of Dyspnea in Patients With COPD","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2016-11-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":124},{"nctId":"NCT03967327","phase":"PHASE3","title":"A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer Pain","status":"UNKNOWN","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2019-04-22","conditions":"Cancer Pain","enrollment":194},{"nctId":"NCT02198924","phase":"PHASE4","title":"Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2014-12","conditions":"Pain, Inflammation","enrollment":246},{"nctId":"NCT01749826","phase":"NA","title":"Inflammatory Responses to Acute and Chronic Opioid Exposure in Humans","status":"TERMINATED","sponsor":"Stanford University","startDate":"2010-01","conditions":"Inflammation","enrollment":20},{"nctId":"NCT01549652","phase":"NA","title":"5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-04","conditions":"Opioid Withdrawal, Physical Dependence","enrollment":133},{"nctId":"NCT00955877","phase":"NA","title":"Extended-release Epidural Morphine for Acute Post-operative Analgesia Following Selective Dorsal Rhizotomy in Children","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2010-03","conditions":"Spastic Cerebral Palsy","enrollment":13},{"nctId":"NCT01631513","phase":"PHASE4","title":"An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)","status":"WITHDRAWN","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2012-08","conditions":"Pain, Chronic Back Pain, Chronic Low Back Pain","enrollment":""},{"nctId":"NCT00314340","phase":"PHASE4","title":"A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2005-11","conditions":"Chronic Pain","enrollment":12},{"nctId":"NCT02641301","phase":"PHASE4","title":"Sustained-release Morphine Pharmacokinetics in Roux-en-Y Gastric Bypass Subjects","status":"UNKNOWN","sponsor":"Hopital Lariboisière","startDate":"2015-12","conditions":"Bypass Complications","enrollment":24},{"nctId":"NCT02455362","phase":"PHASE3","title":"Opioids for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Flinders University","startDate":"2015-05","conditions":"Chronic Obstructive Pulmonary Disease, Dyspnea","enrollment":""},{"nctId":"NCT00943566","phase":"PHASE2","title":"A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer","status":"WITHDRAWN","sponsor":"Labtec GmbH","startDate":"2010-01","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT00261495","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2006-03","conditions":"Pain","enrollment":504},{"nctId":"NCT00916890","phase":"PHASE4","title":"Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain","status":"SUSPENDED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2009-02","conditions":"Chronic Pain","enrollment":320},{"nctId":"NCT00803283","phase":"PHASE3","title":"A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain","status":"TERMINATED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2008-11","conditions":"Cancer Pain","enrollment":2},{"nctId":"NCT00805142","phase":"PHASE2","title":"Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-11","conditions":"Pain, Cancer","enrollment":78},{"nctId":"NCT01309386","phase":"PHASE3","title":"A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2010-08","conditions":"Neoplasms","enrollment":100},{"nctId":"NCT00759759","phase":"PHASE1","title":"Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2004-09","conditions":"Healthy","enrollment":36},{"nctId":"NCT00759954","phase":"PHASE1","title":"Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2004-09","conditions":"Healthy","enrollment":36},{"nctId":"NCT00759356","phase":"PHASE1","title":"Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2004-08","conditions":"Healthy","enrollment":36},{"nctId":"NCT00410540","phase":"PHASE3","title":"A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Pain, Analgesics, Opioid","enrollment":202},{"nctId":"NCT00456898","phase":"PHASE1","title":"Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-01","conditions":"Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sustained Release Morphine Sulfate","genericName":"Sustained Release Morphine Sulfate","companyName":"Labtec GmbH","companyId":"labtec-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sustained Release Morphine Sulfate is a small molecule that acts as a mu opioid receptor agonist, classified as an agonist drug class. It is indicated for various conditions including cancer pain, chronic pain, and opioid-induced constipation, among others.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}